Gotowe bibliografie tematyczne / Udall Foundation

Spis treści

  1. Artykuły w czasopismach
  2. Książki
  3. Części książek

Gotowa bibliografia na temat „Udall Foundation”

Autor: Grafiati
Data publikacji: 29 lipca 2024
Data aktualizacji: 30 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Udall Foundation”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Udall Foundation"

1

Stewart, Mark, Carla Rodriguez-Watson, Adem Albayrak, Julius Asubonteng, Andrew Belli, Thomas Brown, Kelly Cho i in. "COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients". PLOS ONE 16, nr 3 (17.03.2021): e0248128. http://dx.doi.org/10.1371/journal.pone.0248128.

Pełny tekst źródła
Streszczenie:
Background The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydroxychloroquine and azithromycin, alone or in combination, for COVID-19. The COVID-19 Evidence Accelerator convened by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, assembled experts from the health systems research, regulatory science, data science, and epidemiology to participate in a large parallel analysis of different data sets to further explore the effectiveness of these treatments. Methods Electronic health record (EHR) and claims data were extracted from seven separate databases. Parallel analyses were undertaken on data extracted from each source. Each analysis examined time to mortality in hospitalized patients treated with hydroxychloroquine, azithromycin, and the two in combination as compared to patients not treated with either drug. Cox proportional hazards models were used, and propensity score methods were undertaken to adjust for confounding. Frequencies of adverse events in each treatment group were also examined. Results Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients. No treatment groups appeared to have an elevated risk of adverse events. Conclusion Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19.
Style APA, Harvard, Vancouver, ISO itp.
2

Law, Jeanna Wallenta, Danny Idyro, Andrew Schrag, Frank Wolf i Thomas D. Brown. "Abstract 445: Natural history of coagulopathy in patients with cancer infected with COVID19: A real-world data (RWD) analysis". Cancer Research 82, nr 12_Supplement (15.06.2022): 445. http://dx.doi.org/10.1158/1538-7445.am2022-445.

Pełny tekst źródła
Streszczenie:
Abstract Background and Objective: Studies of hospitalized patients (pts) with COVID19 indicate that arterial or venous thrombotic complications occur in up to half of pts. Risk of these severe complications in pts with cancer is unknown. We estimated the incidence of arterial thrombosis (AT) and venous thromboembolism (VT) using RWD from pts with active or history of cancer with COVID19. Methods: Adult pts with cancer receiving treatment in community health systems, with COVID19 identified via ICD code or lab confirmation in 2020, were reviewed for incident AT and VT in a 90 day window following COVID19 diagnosis (index). AT was acute myocardial infarction (MI) or acute ischemic or embolic stroke (S). VT was acute deep venous thrombosis (DVT) or acute pulmonary embolism (PE). Medication use (anticoagulant, antiplatelet, statin) and comorbidities were assessed 6 months and 1 year prior to index, respectively. Results: Median age of 7,591 pts with cancer and COVID19 was 67 years and median follow up was 90 days. 32% of pts were hospitalized within 14 days, 2% received ventilator support, 6% had cardiovascular disease (CVD) and 1% had prior VT. Absolute risk of VT was significantly higher than AT (3% vs. 2%, chi square p= < 0.001), with 161 pts experiencing AT [81 (1%) MI; 80 (1%) S] and 240 pts experiencing VT [99 (1%) DVT; 158 (2%) PE]. This trend held across most subgroups (Table 1). The incidence rate per person-year was 0.094 for AT (0.047 MI, 0.046 S) and 0.141 for VT (0.058 DVT, 0.092 PE). CoxPH models did not show age, sex, comorbidities or medication use as significantly associated with higher probability of AT or VT. Conclusions: RWD showed pts with cancer and COVID19 were at higher risk for VT than AT. Pts who received ventilator support, or had prior VT or prior CVD had highest risk for these events. Severity of these outcomes emphasizes the need for risk reducing interventions. Acknowledgement of Reagan-Udall Foundation and Friends of Cancer Research COVID19 Evidence Accelerator. Table 1. Incidence of arterial and venous events stratified by baseline characteristics at COVID-19 diagnosis among n= 7,591 patients with cancer and infected with COVID19 Absolute Risk, N(%) Incidence Rate Total, N Arterial thrombosis Venous thromboembolism Chi square p-value Arterial thrombosis Venous thromboembolism p-value All 7,591 160 (2.1) 240 (3.2) <0.001 0.0935 0.1414 <0.001 Age 18-44 669 10 (1.5) 10 (1.5) 0.008 0.012 0.061 0.020 45-54 922 4 (0.4) 18 (2) 0.018 0.08 0.003 55-64 1751 26 (1.5) 54 (3.1) 0.062 0.129 0.001 65-74 2054 49 (2.4) 78 (3.8) 0.104 0.165 0.008 75-84 1506 55 (3.7) 60 (4) 0.169 0.184 0.557 85+ 689 24 (3.5) 20 (2.9) 0.18 0.15 0.542 Sex Female 4142 75 (1.8) 126 (3) 0.338 0.078 0.131 0.000 Male 3449 85 (2.5) 114 (3.3) 0.11 0.148 0.030 Race Black 1437 31 (2.2) 61 (4.2) 0.215 0.095 0.187 0.001 White 5054 113 (2.2) 157 (3.1) 0.098 0.137 0.003 Other/Unknown 1100 16 (1.5) 22 (2) 0.061 0.084 0.724 Severity of infection at diagnosis Not hospitalized 5815 78 (1.3) 141 (2.4) 0.0676 0.06 0.105 <0.001 Hospitalized, no ventilator support 1710 76 (4.4) 92 (5.4) 0.21 0.261 0.143 Hospitalized with ventilator support 106 6 (9.1) 7 (10.6) 0.326 0.326 0.965 Existing Cardiovascular disease Yes 467 94 (20.2) 23 (4.9) <0.001 0.105 0.06 <0.001 No 7124 66 (0.9) 217 (3) 0.21 0.261 <0.001 And baseline anticoagulant use 122 27 (22.1) 9 (7.4) <0.001 0.326 0.326 0.602 And no baseline anticoagulant use 7469 67 (19.5) 14 (4.1) 0.088 0.054 <0.001 Previous Venous thromboembolism Yes 312 12 (3.8) 64 (20.5) <0.001 0.184 0.981 <0.001 No 7279 148 (2.0) 176 (2.3) 0.089 0.105 0.542 And baseline anticoagulant use 121 9 (4.7) 22 (11.6) 0.273 0.397 0.969 <0.001 And no baseline anticoagulant use 7470 3 (1.6) 42 (22.1) 0.088 0.127 0.003 Existing Thrombocytosis (via ICD or platelet count >450 x 10^9/L) Yes 185 5 (2.7) 7 (3.8) 1 0.123 0.172 0.087 No 7406 155 (2.1) 233 (3.1) 0.091 0.137 <0.001 Citation Format: Jeanna Wallenta Law, Danny Idyro, Andrew Schrag, Frank Wolf, Thomas D. Brown. Natural history of coagulopathy in patients with cancer infected with COVID19: A real-world data (RWD) analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 445.
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "Udall Foundation"

1

United States. Congress. Senate. Committee on Environment and Public Works. Environmental Policy and Conflict Resolution Act of 1997: Report (to accompany S. 399). [Washington, D.C.?: U.S. G.P.O., 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

US GOVERNMENT. Environmental Policy and Conflict Resolution Act of 1998. [Washington, D.C: U.S. G.P.O., 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

United States. Congress. Senate. Committee on Environment and Public Works. Nominations of Frederic J. Hansen, Paul L. Hill, Devra Lee Davis, Gerald V. Poje, Anne J. Udall, Ronald K. Burton, and David M. Rappoport: Hearing before the Committee on Environment and Public Works, United States Senate, One Hundred Third Congress, second session, on the nominations of Frederic J. Hansen, to be deputy administrator, Environmental Protection Agency; Paul L. Hill ... the Chemical Safety Board, and Anne J. Udall ... the Board of Directors, Morris K. Udall Foundation, September 27, 1994. Washington: U.S. G.P.O., 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

United States. Congress. Senate. Committee on Environment and Public Works. Nominations of Frederic J. Hansen, Paul L. Hill, Devra Lee Davis, Gerald V. Poje, Anne J. Udall, Ronald K. Burton, and David M. Rappoport: Hearing before the Committee on Environment and Public Works, United States Senate, One Hundred Third Congress, second session, on the nominations of Frederic J. Hansen, to be deputy administrator, Environmental Protection Agency; Paul L. Hill ... the Chemical Safety Board, and Anne J. Udall ... the Board of Directors, Morris K. Udall Foundation, September 27, 1994. Washington: U.S. G.P.O., 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

United States. Congress. Senate. Committee on Environment and Public Works. Nominations of Gary Guzy and Anne Jeannette Udall: Hearing before the Committee on Environment and Public Works, United States Senate, One Hundred Sixth Congress, first session, March 4, 1999. Washington: U.S. G.P.O., 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

United States. Congress. Senate. Committee on Environment and Public Works. Nominations of the 108th Congress, first session: Hearing before the Committee on Environment and Public Works, United States Senate, One Hundred Eighth Congress, first session on April 1, 2003. Washington: U.S. G.P.O., 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Internal controls: Corrective actions under way to address control deficiencies at the Morris K. Udall and Stewart L. Udall Foundation : report to congressional requesters. [Washington, D.C.]: United States Government Accountability Office, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

U. S. Government Accountability Offi Gao. Internal Controls: The Morris K. Udall and Stewart L. Udall Foundation Has Made Significant Progress but Needs to Fully Document Certain Policies and Procedures. Independently Published, 2019.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Nominations considered during the second session of the 106th Congress: Hearings before the Committee on Environment and Public Works, United States Senate, One Hundred Sixth Congress, second session, on the nomination of Eric D. Eberhard to be a member, Board of Trustees, Morris K. Udall Scholarship and Excellence in National Environmental Policy Foundation, February 3, 2000; the nomination of W. Michael McCabe to be Deputy Administrator, Environmental Protection Agency, February 3, 2000; the nomination of Ella Wong-Ruskinko to be an Alternate Federal co-chair, Appalachian Regional Commission, June 13, 2000; the nomination of Arthur C. Campbell to be Assistant Secretary for Economic Development, Department of Commerce, June 13, 2000; the nomination of James B. Aidala to be Assistant Administrator for Prevention, Pesticides, and Toxic Substances, Environmental Protection Agency, June 13, 2000. Washington: U.S. G.P.O., 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

US GOVERNMENT. Nominations of Frederic J. Hansen, Paul L. Hill, Devra Lee Davis, Gerald V. Poje, Anne J. Udall, Ronald K. Burton, and David M. Rappoport: Hearing before ... Foundation, September 27, 1994 (S. hrg). For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Udall Foundation"

1

"Morris K Udall and Stewart L Udall Foundation". W The Grants Register 2018, 518–19. London: Palgrave Macmillan UK, 2018. http://dx.doi.org/10.1007/978-1-349-94186-5_799.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

"Morris K Udall and Stewart L Udall Foundation". W The Grants Register 2019, 518. London: Palgrave Macmillan UK, 2018. http://dx.doi.org/10.1007/978-1-349-95810-8_829.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii